A new review maps how engineered fungi, yeasts, and microalgae could displace plant seed oils as the dominant source of the ...
Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as ...
Scientists edited the promoter of the rice gene OsGTL1 to lower stomatal density, raising instantaneous water use efficiency ...
March 25, 2020. A letter was issued by the Center for Food Safety and Applied Nutrition of the U.S. Food and Drug ...
CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026 ...
CRISPR Therapeutics and Vertex Pharmaceuticals have noted that the medicine currently has an addressable market of roughly 60 ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.39, moving -1.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%.
Human cells hold about two meters (6.6 feet) of DNA, folded and compacted to fit inside a nucleus. That packing is essential ...
Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.
Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...
Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results